Patents by Inventor Jordi Molgo
Jordi Molgo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190004043Abstract: The present invention relates to a device for detecting neurotoxins or ligands, a method for manufacturing an analysis device, and use of an analysis device detecting and quantifying neurotoxins or ligands. The present invention finds an application in the medical field and also in food field, in particular in the field of monitoring seafood, in the field of monitoring freshwater reservoirs, in the field of medical research, and in the field of the biological analysis and characterization of molecules.Type: ApplicationFiled: December 15, 2016Publication date: January 3, 2019Inventors: Romulo ARAOZ, Jordi MOLGO, Denis SERVENT, Gilles MOURIER, Pascal KESSLER
-
Patent number: 10073089Abstract: The présent invention relates to a method for manufacturing an analysis device including torpédo membrane fragments immobilized at the surface thereof, to the resulting analysis device, and to the use of said device for detecting, purifying, and characterizing molécules acting on nicotinic acetylcholine receptors. The présent invention is useful in the field of monitoring seafood, monitoring neurotoxic phytoplankton for the shellfish industry, monitoring the quality of bathing waters along tourist beaches, the field of monitoring fresh water reserves, the field of médical research, the field of the biological analysis and characterization of molécules, e.g., non-radioactive assays of the movement of the ligand-receptor bond on an ELISA-type microplate, thereby enabling compétitive agonists and antagonists of targets to be detected, e.g., of highly sensitive receptors.Type: GrantFiled: January 24, 2012Date of Patent: September 11, 2018Assignee: ABRAXIS LLCInventors: Romulo Araoz, Hoang-Oanh Nghiem, Jordi Molgo, Luis Botana, Natalia Vilarino
-
Publication number: 20180148483Abstract: The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.Type: ApplicationFiled: February 21, 2017Publication date: May 31, 2018Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Philippe FAVREAU, Evelyne BENOIT, Jordi MOLGO, Reto STOCKLIN
-
Publication number: 20170226166Abstract: The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and /or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.Type: ApplicationFiled: February 21, 2017Publication date: August 10, 2017Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.), ACTIVENInventors: Philippe FAVREAU, Evelyne BENOIT, Jordi MOLGO, Reto STOCKLIN
-
Patent number: 9644011Abstract: The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.Type: GrantFiled: January 11, 2013Date of Patent: May 9, 2017Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Philippe Favreau, Evelyne Benoit, Jordi Molgo, Reto Stöcklin
-
Publication number: 20130303405Abstract: The présent invention relates to a method for manufacturing an analysis device including torpédo membrane fragments immobilized at the surface thereof, to the resulting analysis device, and to the use of said device for detecting, purifying, and characterizing molécules acting on nicotinic acetylcholine receptors. The présent invention is useful in the field of monitoring seafood, monitoring neurotoxic phytoplankton for the shellfish industry, monitoring the quality of bathing waters along tourist beaches, the field of monitoring fresh water reserves, the field of médical research, the field of the biological analysis and characterization of molécules, e.g., non-radioactive assays of the movement of the ligand-receptor bond on an ELISA-type microplate, thereby enabling compétitive agonists and antagonists of targets to be detected, e.g., of highly sensitive receptors.Type: ApplicationFiled: January 24, 2012Publication date: November 14, 2013Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS, UNIVERSIDAD DE COMPOSTELLA, INSTITUT PASTEURInventors: Romulo Araoz, Hoang-Oanh Nghiem, Jordi Molgo, Luis Botana, Natalia Vilarino
-
Publication number: 20130203676Abstract: The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.Type: ApplicationFiled: January 11, 2013Publication date: August 8, 2013Inventors: Philippe Favreau, Evelyne Benoit, Jordi Molgo, Reto Stöcklin
-
Publication number: 20120087969Abstract: In one embodiment, the present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. An embodiment of the invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.Type: ApplicationFiled: November 8, 2006Publication date: April 12, 2012Applicants: Centre National de la Recherche Scientifique (C.N.R.S.), Atheris LaboratoriesInventors: Philippe Favreau, Evelyne Benoit, Jordi Molgo, Reto Stöcklin
-
Publication number: 20120040930Abstract: The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.Type: ApplicationFiled: January 13, 2006Publication date: February 16, 2012Inventors: Catherine Guillou, Jean-Yves Lallemand, Thibault Sauvaítre, Jordi Molgo, Denyse Herlem, Daniel Guenard, Françoise Khuong-Huu
-
Patent number: 7923216Abstract: A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.Type: GrantFiled: September 16, 2003Date of Patent: April 12, 2011Assignees: Institut Pasteur, Centre Nationale de la Recherche ScientifiqueInventors: Sylvie Roux, Philippe Brulet, Cécile Saint Cloment, Julien Barbier, Jordi Molgo
-
Publication number: 20100260758Abstract: The invention relates to means for in vivo delivery of a composition into the human or animal central nervous system or spinal cord, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxoid in association with at least a molecule having a biological function, and said molecule is capable of in vivo retrograde axonal transport and transynaptic transport into the CNS or spinal cord of the human or animal. In a particular embodiment, the composition comprises a fragment C and a fragment B of tetanus toxoid or a fraction thereof of at least 11 amino acid residues. The composition can further comprise a fraction of fragment A of tetanus toxoid.Type: ApplicationFiled: November 23, 2009Publication date: October 14, 2010Inventors: Sylvie ROUX, Philippe Brulet, Cecile Saint Cloment, Julien Barbier, Jordi Molgo
-
Publication number: 20100081197Abstract: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells allows visualization of an active synapse. Also, a method for screening molecules capable of modulating synapse activity is provided. A kit useful for the early diagnosis of neurodegenerative disease comprises a biomarker comprising at least fragment C of tetanus toxin and a reporter protein.Type: ApplicationFiled: September 14, 2007Publication date: April 1, 2010Inventors: Sylvie Roux, Philippe Brulet, Cecile Saint Cloment, Julien Barbier, Jordi Molgo
-
Patent number: 7572774Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.Type: GrantFiled: January 22, 2002Date of Patent: August 11, 2009Assignee: Centre National de la Recherche Scientific (C.N.R.S.)Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
-
Publication number: 20070225237Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and /or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.Type: ApplicationFiled: May 11, 2007Publication date: September 27, 2007Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (C.N.R.S.)Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
-
Publication number: 20070225235Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.Type: ApplicationFiled: May 11, 2007Publication date: September 27, 2007Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (C.N.R.S.)Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
-
Publication number: 20070225236Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.Type: ApplicationFiled: May 11, 2007Publication date: September 27, 2007Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (C.N.R.S.)Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
-
Publication number: 20060275327Abstract: The invention relates to means for in vivo delivery of a composition into the human or animal central nervous system or spinal cord, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxoid in association with at least a molecule having a biological function, and said molecule is capable of in vivo retrograde axonal transport and transynaptic transport into the CNS or spinal cord of the human or animal. In a particular embodiment, the composition comprises a fragment C and a fragment B of tetanus toxoid or a fraction thereof of at least 11 amino acid residues. The composition can further comprise a fraction of fragment A of tetanus toxoid.Type: ApplicationFiled: March 15, 2006Publication date: December 7, 2006Inventors: Sylvie Roux, Philippe Brulet, Cecile Cloment, Julien Barbier, Jordi Molgo
-
Publication number: 20040170651Abstract: A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.Type: ApplicationFiled: September 16, 2003Publication date: September 2, 2004Inventors: Sylvie Roux, Philippe Brulet, Cecile Saint Cloment, Julien Barbier, Jordi Molgo
-
Publication number: 20020115617Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoguinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.Type: ApplicationFiled: January 22, 2002Publication date: August 22, 2002Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei